ABK Biomedical is a Halifax-based medical device company focused on researching, developing, and commercializing embolotherapy products that improve outcomes for patients with benign and malignant hypervascular tumors. Its flagship product, Eye90 microspheres®, is an imageable yttrium-90 radioembolization therapy that has received FDA Breakthrough Device Designation and is currently being evaluated in the Route90 FDA IDE pivotal trial for liver cancer treatment. The company owns intellectual property surrounding inorganic polymer microspheres and proprietary delivery systems, and it operates its own R&D and manufacturing facilities. Proceeds from its latest funding will be used to advance clinical operations, prepare for Eye90 microspheres commercialization, and expand manufacturing and supply-chain capacity. ABK also plans to drive additional product innovation across its embolic platforms. The oversubscribed Series D round reinforces strong investor confidence dating back to the firm’s Series B financing in 2019.

Total raised

$95M

Funding rounds

3

Latest round

Series D

Latest activity

Oct 2025